231 related articles for article (PubMed ID: 17301509)
1. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
[TBL] [Abstract][Full Text] [Related]
2. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
Lamotte M; Annemans L; Evers T; Kubin M
Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
[TBL] [Abstract][Full Text] [Related]
3. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
6. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
[TBL] [Abstract][Full Text] [Related]
7. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; PiƱol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
[TBL] [Abstract][Full Text] [Related]
9. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone M; Earnshaw S; Tice JA; Pletcher MJ
Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
Pignone M; Earnshaw S; Pletcher MJ; Tice JA
Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease.
Michaud TL; Abraham J; Jalal H; Luepker RV; Duval S; Hirsch AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26702086
[TBL] [Abstract][Full Text] [Related]
16. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
Carlton R; Coppolecchia R; Khalaf-Gillard K; Lennert B; Moradi A; Williamson T; Cameron J
J Manag Care Spec Pharm; 2018 Nov; 24(11):1102-1111. PubMed ID: 30362916
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
Jiang M; Li P; You JH; Zheng X; Deng J; Zhao M; Feng L; Fang Y
PLoS One; 2019; 14(12):e0224580. PubMed ID: 31790409
[TBL] [Abstract][Full Text] [Related]
20. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Noubiap JJ; Nansseu JR
Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]